ASTRA
Adding a MEK inhibitor to boost iodine uptake before ablation did not improve complete remission rates, cooling the 'redifferentiation for everyone' idea.
Complete remission at 18 months 40% vs 38.5%; no benefit. Redifferentiation remains reserved for selected radioiodine-refractory patients, where MEK or BRAF/MEK inhibitors can restore uptake in about half.
- 40 vs 38.5 out of 100 had no sign of cancer on scans or tests with Selumetinib + RAI compared with Placebo + RAI; 1.5 more per 100.
- Roughly one extra person helped for every 67 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- These results apply to the people the trial enrolled: High-risk differentiated thyroid cancer: selumetinib + adjuvant radioiodine vs placebo + radioiodine. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
401 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Complete remission at 18 monthsprimary | Selumetinib + RAI | — | 40% | — | — | link |
| Placebo + RAI | — | 38.5% |
Pages like this
not linked directly; found by shared links- TrialRELATIVITY-098
Shares the tags failure, lesson:adjuvant-vs-active-disease.
- TermRadioiodine-refractory (RAI-R) thyroid cancer
Shares MAPK inhibitor redifferentiation → radioiodine, Radioiodine therapy and whole-body iodine scanning, Thyroid cancer.
- TrialHiLo
Shares Radioiodine therapy and whole-body iodine scanning, Thyroid cancer.
- TermThyroidectomy
Shares Radioiodine therapy and whole-body iodine scanning, Thyroid cancer.
- TrialIoN
Shares Radioiodine therapy and whole-body iodine scanning, Thyroid cancer.
- TrialESTIMABL2
Shares Radioiodine therapy and whole-body iodine scanning, Thyroid cancer.
- ProductNintedanib
Shares Small-molecule kinase inhibitors and the tag failure.
- ProductRadioactive iodine (I-131)
Shares MAPK inhibitor redifferentiation → radioiodine, Radioiodine therapy and whole-body iodine scanning, Thyroid cancer.